Journal
CLINICAL BIOCHEMISTRY
Volume 46, Issue 3, Pages 202-208Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2012.11.006
Keywords
Visfatin; Diabetes; Morbidly obese women; Non-alcoholic fatty liver disease
Categories
Funding
- Ministerio de Ciencia e Innovacion of the government of Spain [SAF 2008-02278, SAF 2012-35198]
- Fondo de Investigacion Sanitaria [PS09/01778]
- Agencia de Gestio d'Ajuts Universitaris i de Recerca [AGAUR 2009 SGR 959]
- Grup de Recerca en Medicina Aplicada URV [2010PFR-URV-B2-14]
- Fundacion Biociencia
Ask authors/readers for more resources
Objectives: The few studies on the physiopathological role of visfatin in morbid obesity and the related metabolic diseases have led us to examine visfatin levels and its liver gene expression in morbidly obese women with non-alcoholic fatty liver disease (NAFLD). Design and methods: We examined the circulating levels of visfatin by ELISA in serum samples from 95 morbidly obese women (MO) (BMI>40 kg/m(2)) who underwent bariatric surgery and 38 normal weight control women (BMI<25 kg/m(2)). We analysed visfatin liver and adipose tissue mRNA expression by RT-PCR. We evaluated the circulating levels and gene expression of adiponectin, resistin, RBP4, TNF alpha, IL6 and CRP. Results: Serum visfatin was significantly higher in MO compared with controls, and also in MO with NAFLD was significantly higher than MO with normal liver. We found that NAFLD diabetic patients presented similar serum visfatin levels than non-diabetic. Serum visfatin correlated with IL6 (r = 0.496; p<0.001) and CRP levels (r = 0.241; p = 0.049). Liver visfatin expression was significantly higher in MO compared to controls and was also significantly higher in MO with NAFLD than in MO with normal liver. Visfatin liver expression correlated positively with resistin (r = 0.436, p = 0.018) and TNFa expression (r = 0.328, p = 0.028). Visfatin expression in adipose tissues was similar among the MO groups analysed. Conclusion: Serum visfatin and its liver expression are higher in MO women with NAFLD, irrespective of the presence of diabetes. Serum visfatin and its liver expression correlate positively with pro-inflammatory factors. These findings suggest that visfatin may be a molecule related with fat inflammation in morbid obesity and fatty liver disease. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available